Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (ACB) has announced significant updates on its Business Transformation Plan, including an SG&A run rate target of approximately $42 million for Q1 2021. The company is focused on enhancing margins and profitability through personnel restructuring, with a 25% reduction in SG&A staff and a 30% reduction in production staff. Additionally, Aurora is consolidating its production facilities to improve efficiency and expects to report a positive adjusted EBITDA for Q1 2021. However, the company anticipates up to $60 million in impairment charges related to facility closures.